Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes ...

RSV vaccination for adults aged 60+ could prevent significant LRTD cases, hospitalizations, and deaths over five years. A 5-percentage-point increase in vaccine uptake could avert over 222,000 LRTD ...

The Centers for Disease Control and Prevention (CDC) has expanded the RSV vaccine recommendation to include adults 50 and older who are at higher risk of severe illness. Despite the eligibility ...

Estimated vaccine effectiveness was significantly lower among immunocompromised than immunocompetent adults and for those with cardiovascular disease versus those without. HealthDay News — The ...

RSV can cause serious complications in older adults 🏥 ...

A multi-institutional collaboration led by the Center for Translational Cardiology and Pragmatic Randomized Trials at Copenhagen University Hospital-Herlev and Gentofte, University of Copenhagen, ...

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

The MarketWatch News Department was not involved in the creation of this content. -- Arexvy will account for the majority share of publicly funded RSV vaccine doses provided in the country for ...

The UK Health Security Agency (UKHSA) has reported that the respiratory syncytial virus (RSV) vaccine is around 82% effective in preventing hospitalisation among adults aged 75-79. The data come from ...

The Vaccine Integrity Project, in collaboration with the American Medical Association (AMA), has announced the kickoff of a ...

Estimated vaccine effectiveness was significantly lower for immunocompromised adults and those with CVD. (HealthDay News) — The respiratory syncytial virus (RSV) vaccine reduces RSV-associated ...